XOFLUZA was as safe and well tolerated as placebo in clinical trials *

Across 3 clinical trials, XOFLUZA had a similar or lower adverse event rate than placebo—even among patients at high risk of developing flu complications. 1*

The safety and efficacy of XOFLUZA have not been established in pediatric patients under 12 years of age or weighing less than 40 kg.

*Based on combined data of 3 trials, a total of 1640 subjects received XOFLUZA: 1334 (81%) were adults (aged 18 to 64 years of age) and 209 (13%) were adults 65 years of age or older and 97 (6%) were adolescents (aged 12 to 17 years). Of these, 1440 subjects received XOFLUZA at the recommended dose.

Broad antiviral activity

XOFLUZA is active against a broad range of flu strains, including those resistant to oseltamivir. 1